GTx, Inc. Sued by Investor
Robbins Arroyo LLP are investigating claims on behalf of investors of GTx, Inc. (NASDAQ: GTXI) (“GTx”). GTx develops and commercializes small molecules for the treatment of cancer, cancer supportive care, and other serious medical conditions.
GTx Reports Disappointing Results for Enobosarm Trials
Robbins Arroyo’s investigation concerns whether GTx’s officers and directors made misleading statements to the investing public. On August 19, 2013, GTx announced the results of two of its Phase III enobosarm clinical trials. Enobosarm was developed to prevent and treat muscle wasting in patients with non-small cell lung cancer. GTx announced that the clinical trials for enobosarm failed to meet the goals of improving body mass and physical function in cancer patients, as agreed upon with the U.S. Food and Drug Administration. On this news, GTx stock declined $2.72, or nearly 66%, to close at $1.43 on August 19, 2013.
If you invested in GTx and would like to discuss your shareholder rights, please contact attorney Darnell R. Donahue at (800) 350-6003 or you can complete the form below and we will contact you directly.
Shareholder InformationSend This Post